drugset / Trial / NCT02136992
Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Phase 2
Completed
160 enrolled
Shanghai Pulmonary Hospital, Shanghai, China
Nanjing Chia-tai Tianqing Pharmaceutical · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Pirfenidone as anti-fibrosis drug developed in recent years demonstrated the potential anti- fibrotic effect, but so far there were no domestic studies about pirfenidone's efficacy and safety evaluation in china. The aim of this study was to evaluate the efficacy and safety of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) through the observation of a large sample of clinical cases.
Timeline
- Start
- 2011-12
- Primary completion
- 2013-06
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pirfenidone | Small molecule | 200 mg | — |